intervention,cost_effectiveness,stdev,source
Research - HIV,303.6788321,23736.173393361463,FHI
Research - Malaria,801.6557552999999,67817.2531556002,FHI
Research - TB,116.92257009999999,6958.190391689557,FHI
Research - Diarrhoeal diseases,3549.783221,286578.6965590446,FHI
Research - Hookworm,120.52655990000001,5099.0571812595,FHI
Research - Ascariasis,187.7757689,8193.987406358423,FHI
Research - Trichuriasis,251.3360511,11972.794951650587,FHI
Research - Lymphatic filariasis,59.91307178,2482.9031096929875,FHI
Research - Schistosomiasis,38.47714042,1623.9408994361875,FHI
Research - Onchocerciasis,18.36571832,756.2606520824662,FHI
Research - Dengue,0.3735479903,8.223786927174988,FHI
Research - Leishmaniasis,1703.723172,191421.5566238122,FHI
Research - Chagas disease,534.9673442,61260.90487924331,FHI
Research - Trypanosomiasis,802.7856649,107344.56932565401,FHI
Research - Meningititis,1732.5276829999998,150346.12251771212,FHI
Research - Typhoid and paratyphoid fever,709.0926718,53697.85267439134,FHI
Research - Multiple salmonella infections,753.6160471,46757.22591019181,FHI
Research - Leprosy,824.5218899,104639.48389870102,FHI
Research - Trachoma,17.06625626,685.7495338323076,FHI
Deworm the World,12.039436799377382,11.307933850696788,GW
Schistosomiasis Control Initiative,9.064981033005992,8.657475087774499,GW
Sightsavers,4.8944702111241245,4.598517108864676,GW
GiveDirectly,1.060327928590548,0.38096115201768715,GW
Against Malaria Foundation,3.572679373597565,2.964296538367636,GW
Malaria Consortium,3.222605618329421,2.162316158738712,GW
iodine supplementation,41.41890997158105,41.364215337848066,GW
Household lead pipe replacement,4.519663487284017,14.533889728565203,GW
"ACE inhibitor and beta-blocker, with diuretics",6.666666667,2.024291498,DCP2
Advertising ban and reduced access to beverage retail,2.475247525,6.756756755,DCP2
Annual mass drug administration,66.66666667,21.739130435,DCP2
"Antipsychotic drugs with optional psychosocial treatment, communitybased",0.10168802119999999,0.033955857385,DCP2
"Antipsychotic drugs with optional psychosocial treatment, hospitalbased",0.08389261745,0.031987716714999996,DCP2
Antiretroviral therapy,1.084598698,0.43706293705,DCP2
Aspirin and dipyridamole,12.34567901,21.739130435,DCP2
"Aspirin, betablocker, and optional ACE inhibitor",1.4534883719999998,1.052631579,DCP2
Ayurvedic treatment and levodopa or carbidopa,0.8833922261,0.657894737,DCP2
BCG vaccine,14.70588235,18.51851852,DCP2
Blood and needle safety,11.9047619,9.25925926,DCP2
Case management at community or facility level,7.751937984,3.164556962,DCP2
Case management at hospital level,0.2207505519,0.1548946716,DCP2
Cholera or rotavirus immunization,0.3687315634,1.091703057,DCP2
Condom promotion and distribution,12.19512195,8.333333335,DCP2
Construction and promotion of basic sanitation where facilities are limited,7.092198582000001,1.9305019305000002,DCP2
Diethyl carbamazine salt,45.45454545,11.904761905,DCP2
Directly observed short-course chemotherapy,3.3222591360000004,1.0706638115,DCP2
Directly observed short-course chemotherapy,9.803921569,2.8735632185,DCP2
Drugs with optional episodic or maintenance psychosocial treatment,0.5885815185000001,0.23992322454999998,DCP2
Drugs with optional psychosocial treatment,1.36239782,0.7142857145,DCP2
"Enforcement of seatbelt laws, promotion of child restraints and random driver breath testing",0.4083299306,0.1724137931,DCP2
Excise tax,0.7262164125,1.9607843135,DCP2
"Excise tax, advertising ban, with brief advice",1.584786054,8.333333335,DCP2
"Family, community, or clinical neonatal package",2.898550725,38.46153846,DCP2
Heparin and recombinant tissue plasminogen activator,0.5058168943,0.35790980674999995,DCP2
Improved water and sanitation at current coverage of amenities and other interventions,0.23894862600000003,0.11322463769999999,DCP2
"Increased speeding penalties, enforcement, media campaigns, and speed bumps",47.61904762,14.285714285,DCP2
Insecticidetreated bednets,90.90909091,41.666666665,DCP2
Intermittent preventive treatment in pregnancy with drug other than sulfadoxinepyrimethamine,142.8571429,55.55555555,DCP2
Intermittent preventive treatment in pregnancy with sulfadoxinepyrimethamine,52.63157895,45.454545455,DCP2
Isoniazid treatment,0.075999392,0.06741270055,DCP2
Isoniazid treatment,5.076142132,1.6501650165000001,DCP2
Legislation substituting 2% of trans fat with polyunsaturated fat at $6 per adult,1.193317422,0.3909304144,DCP2
"Lithium, valproate, with optional psy-chosocial treatment, community-based",0.3212335368,0.40650406505000003,DCP2
"Lithium, valproate, with optional psychosocial treatment, hospital-based",0.2263980077,0.3022974607,DCP2
Management of drug resistance,3.1446540880000002,2.262443439,DCP2
Management of drug resistance,4.830917874,45.454545455,DCP2
Mother-to-child transmission prevention,5.208333333,1.3513513515,DCP2
Peer and education programs for high-risk groups,27.02702703,8.06451613,DCP2
Polypill by absolute risk approach,0.469924812,0.184501845,DCP2
Residual household spraying,58.82352941,33.333333335,DCP2
Second-line treatment with phenobarbital and lamotrigine or surgery,0.3303600925,7.575757575,DCP2
Staffed community ambulance,8.333333332999999,4.2016806725,DCP2
"Statin, with aspirin and betablocker with ACE inhibitor",0.4930966469,1.519756839,DCP2
Surgical ward or services in district hospital or community clinic,7.352941176,3.0674846625,DCP2
Tetracycline or azithromycin,0.1595150742,0.09934432744999999,DCP2
Treatment of Kaposi's sarcoma,0.01906614044,0.01430124135,DCP2
Treatment of opportunistic infections,6.41025641,1.628664495,DCP2
Tuberculosis coinfection prevention and treatment,8.26446281,17.24137931,DCP2
Vector control,0.38971161340000005,0.43591979075000004,DCP2
Vector control,6.25,2.1367521369999998,DCP2
Voluntary counseling and testing,21.27659574,6.666666665,DCP2
BA only (5 min),2.185792349726776,0.7272727272727273,NICE
BA [5 min plus nicotine replacement therapy (NRT)],0.7582938388625593,0.2524455664247397,NICE
BA (5 min plus self-help),4.324324324324325,1.4414414414414416,NICE
Exercise prescriptions,20.779220779220783,5.755395683453238,NICE
Accelerated partner therapy—doxycycline,0.11408199643493762,0.08556149732620322,NICE
Accelerated partner therapy—azithromycin,0.08236808236808237,0.06177606177606178,NICE
Brief counselling,0.13121207151057898,3.508771929824561,NICE
Information motivation and behaviour skills,0.11313017040231917,0.10370754472387865,NICE
Enhanced counselling,0.03508310310046924,0.06659452260051611,NICE
Life-skills training,0.4581901489117985,0.14414414414414414,NICE
Urban trail,0.15318334131163236,0.035539760106619286,NICE
PA counselling,1.851851851851852,1.0825439783491206,NICE
Smoking cessation—general population: incentive schemes NRT,4.4692737430167595,1.2779552715654952,NICE
Smoking cessation—general population: client centred,32.0,1.830663615560641,NICE
Smoking cessation—general population: proactive telephone counselling,3.747072599531616,0.5468215994531785,NICE
Smoking cessation—general population: recruitment to quit and win,6.153846153846154,0.05959919541086195,NICE
Smoking cessation—general population: identify smokers through other means,3.1746031746031744,0.1951219512195122,NICE
Smoking cessation—general population: pharmacist based,2.9304029304029307,3.686635944700461,NICE
Smoking cessation —general population: dentist based,5.298013245033113,8.791208791208792,NICE
Smoking cessation—disadvantaged groups: client-centred social marketing,1.0230179028132993,0.1335113484646195,NICE
Smoking cessation—disadvantaged groups: NHS SSS,0.5956813104988832,2.6490066225165565,NICE
Smoking cessation—disadvantaged groups: pharmacist based,0.5077753094255791,0.1885902876001886,NICE
Statins—general population: pharmacist based,0.32706459525756343,0.12146978439113272,NICE
Statins—disadvantaged groups: invitation for screening by GP,0.36815462494247586,1.1560693641618496,NICE
Advice about PA,0.04456824512534819,0.04123711340206186,NICE
Individual stress management,0.32012805122048826,0.06919816624859441,NICE
Curricular,0.22222222222222224,0.07497656982193066,NICE
Screening and BA during GP consultation,0.48484848484848486,0.12121212121212122,NICE
Intralesional and intramuscular administration of the pentavalent antimonial drug sodium stibogluconate,0.625,7.489027147041027,GHCEA
Policy intervention to reduce sodium consumption by 10%,26.31578947368421,242.13310026955267,GHCEA
Policy intervention to reduce sodium consumption by 10%,2.941176470588235,29.215781827424166,GHCEA
Policy intervention to reduce sodium consumption by 10%,10.309278350515465,98.34420747401288,GHCEA
Policy intervention to reduce sodium consumption by 10%,0.03571428571428572,0.34452326167468833,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,200.0,961.1786201119693,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),5.263157894736842,13.421091843512349,GHCEA
Policy intervention to reduce sodium consumption by 10%,4.545454545454545,40.01177295766032,GHCEA
Policy intervention to reduce sodium consumption by 10%,0.058823529411764705,0.5327731081111272,GHCEA
Policy intervention to reduce sodium consumption by 10%,8.333333333333334,82.47830661939524,GHCEA
Mass media campaign to promote tobacco cessation,0.2631578947368421,25.472247677479576,GHCEA
Pharmacological therapy for high blood pressure,0.2941176470588235,58.86009911468893,GHCEA
Pharmacological therapy of high cholesterol,0.058823529411764705,10.90370939127741,GHCEA
Rotarix vaccine,0.1388888888888889,0.189897455374098,GHCEA
Therapy with Bupropion for Tobacco Cessation,0.014285714285714285,2.58673958715104,GHCEA
Policy intervention to reduce sodium consumption by 10%,6.25,66.71302963149412,GHCEA
Risperidone (5 mg/day),0.025,96.21144152879333,GHCEA
Methylphenidate,0.08333333333333333,0.6190348563480501,GHCEA
SunSmart program (skin cancer prevention program) in a well-resourced state,0.07142857142857144,0.7985549646889848,GHCEA
Cognitive behavioral therapy with private psychiatrists,0.052631578947368425,0.3471978107343412,GHCEA
Pre-diabetes screen screen plus diet and exercise to prevent or slow the onset of diabetes,0.05,0.49909685293061545,GHCEA
Multiple family groups:  Family engagement sessions and psychoeducation,0.06666666666666667,0.18571045690441504,GHCEA
Active After-school Communities Program (AASC)--physical activity co-ordinators develop and deliver physical activity program specific to each school,0.01694915254237288,0.06388439717511878,GHCEA
Residential treatment + naltrexone,0.01,0.09285522845220752,GHCEA
Group-based psychological intervention following opportunistic screening  to prevent depression,0.058823529411764705,0.14788054901647862,GHCEA
Angiotensin-converting enzyme (ACE) inhibitors via mainstream general practitioner to prevent cardiovascular disease,0.037037037037037035,0.2101460433392065,GHCEA
Selective serotonin reuptake inhibitors as second line treatment,0.052631578947368425,0.1947695035826792,GHCEA
Tricyclic antidepressants - imipramine,0.07142857142857144,0.24723063922259583,GHCEA
Knee replacement surgery,0.1,1.5971099293779696,GHCEA
Laparoscopic adjustable gastric banding plus standard care,0.3225806451612903,2.4799843623881515,GHCEA
HMG-CoA reductase inhibitors (statins) via mainstream general practitioner to prevent cardiovascular disease,0.0196078431372549,0.3629795294040839,GHCEA
Cognitive behavioral therapy,0.3448275862068965,2.5759837570612407,GHCEA
"Looma Healthy Lifestyle- community based intervention to reduce morbidity from diabetes and cardiovascular disease including heath education, exercise",0.005555555555555556,0.03802642688995165,GHCEA
Orlistat treatment,0.0047619047619047615,0.046973821452293216,GHCEA
Nicotine replacement therapy for 6-12 weeks,0.0625,0.420292086678413,GHCEA
Maintenance treatment with tricyclic antidepressants,0.2702702702702703,9.981937058612308,GHCEA
Brief alcohol intervention + telemarketing + support,0.11494252873563218,0.44119058822595836,GHCEA
Screening of children in preschool for depression and anxiety,0.12195121951219512,0.4137590490616501,GHCEA
Walking School Bus (WSB) program to increase the number of children of primary school age walking to school (accompanied by volunteer adults),0.001851851851851852,0.002584320274074384,GHCEA
Cognitive behavioral therapy-public psychiatrists,0.052631578947368425,0.33273123528707693,GHCEA
Maintenance treatment with selective serotonin re-uptake inhibitors,0.06666666666666667,2.6618498822966155,GHCEA
Drug treatment with selective serotonin re-uptake inhibitors SSRIs for acute episodes and 6 months continuation,0.08333333333333333,1.1407928066985495,GHCEA
Residential treatment - alcohol,0.0058823529411764705,0.058717276815366516,GHCEA
"Pre-diabetes screen plus Metformin, diet and exercise to prevent or slow the onset of diabetes",0.014285714285714285,0.06884094523180902,GHCEA
Clozapine (400 mg/day),0.02857142857142857,0.25759837570612404,GHCEA
"Current treatment: all patients receiving antipsychotic medication (haloperidol or other typical antipsychotic, atypical antipsychotic, clozapine) and smaller proportion receiving psychosocial intervention",0.005263157894736842,0.04597613923098093,GHCEA
Olanzapine (15 mg/day),0.03225806451612903,0.3629795294040839,GHCEA
Cognitive behavioral therapy with private psychiatrist,0.03571428571428572,0.12099317646802799,GHCEA
Drink driving mass media,0.0625,0.020581313522911975,GHCEA
Trauma focused cognitive behavioral therapy 8-12 individual weekly sessions,0.11363636363636363,0.39144851210244347,GHCEA
Hip replacement surgery,0.23255813953488375,3.9927748234449236,GHCEA
Clozapine (400 mg/day),0.052631578947368425,0.2661849882296615,GHCEA
Behavioral family management,0.05,0.15657940484097738,GHCEA
Pre-diabetes screen plus Orlistat to prevent or slow the onset of diabetes,0.011494252873563218,0.22182082352471796,GHCEA
Education to improve decision making relating to prostate specific antigen testing,0.1,0.4304878515843583,GHCEA
Policy intervention to reduce sodium consumption by 10%,1.1235955056179776,11.09951997621773,GHCEA
Cognitive behavioral therapy-public psychologist,0.17543859649122806,0.9981937058612309,GHCEA
Serotonin reuptake inhibitors - paroxetine,0.03225806451612903,0.12879918785306202,GHCEA
Treatment with bupropion for a period of 7 weeks,0.12987012987012986,1.9963874117224618,GHCEA
Olanzapine (15 mg/day),0.013157894736842106,0.06825256108452861,GHCEA
Indicated psychological interventions,0.05,0.14889524252106665,GHCEA
Trauma focused cognitive behavioral therapy 8-12 individual weekly sessions,0.05555555555555556,0.7259590588081678,GHCEA
Tricyclic antidepressants TCAs for acute major depressive episodes plus a 6-month continuation phase after remission of symptoms,0.2173913043478261,2.6618498822966155,GHCEA
Sibutramine treatment,0.008333333333333333,0.08872832940988719,GHCEA
Pre-diabetes screen plus Acarbose to prevent or slow the onset of diabetes,0.03125,0.07326192336596188,GHCEA
Cognitive behavioral therapy-public psychiatrist,0.04761904761904762,0.215825666132158,GHCEA
Cognitive behavioral therapy with public psychologist,0.20833333333333334,0.7194188871071934,GHCEA
Pre-diabetes screen plus exercise to prevent or slow the onset of diabetes,0.038461538461538464,0.12099317646802799,GHCEA
Pre-diabetes screen plus diet to prevent or slow the onset of diabetes,0.030303030303030304,0.06388439717511878,GHCEA
Risperidone (5 mg/day),0.058823529411764705,665.4624705741538,GHCEA
Low dose diuretics to prevent cardiovascular disease,0.10416666666666667,0.3442047261590451,GHCEA
Cognitive dissonance – school based bulimia and anorexia preventative intervention,0.00909090909090909,0.08441027490264522,GHCEA
Cognitive behavioral therapy with public psychiatrist,0.038461538461538464,0.12285460995215149,GHCEA
"Optimal treatment with antipsychotic medication (haloperidol or other typical antipsychotic, atypical antipsychotic, clozapine) and psychosocial intervention based on severity groups",0.01,0.05480666039978207,GHCEA
Serotonin and noradrenaline reuptake inhibitors - venlafaxine,0.052631578947368425,0.33273123528707693,GHCEA
Cognitive behavioral therapy individual sessions plus two parent/family sessions + general practitioner (GP) visit for diagnosis and referral,0.04347826086956522,0.14009736222613767,GHCEA
Cognitive behavioral therapy-public psychologist,0.052631578947368425,0.2661849882296615,GHCEA
Pre-diabetes screen plus Metformin to prevent or slow the onset of diabetes,0.052631578947368425,0.420292086678413,GHCEA
Selective serotonin reuptake inhibitors as first-line treatment,0.052631578947368425,0.1996387411722462,GHCEA
Behavioral intervention in families,0.18518518518518517,0.5703964033492748,GHCEA
Cognitive behavioral therapy-private psychologist,0.058823529411764705,0.3802642688995166,GHCEA
General practitioner referral to exercise physiologist,0.015384615384615384,0.07066858094592784,GHCEA
Brief alcohol intervention,0.16949152542372883,1.5971099293779696,GHCEA
Cognitive behavioral therapy-private psychiatrist,0.04545454545454545,0.27536378092723607,GHCEA
Cognitive behavioral therapy with public psychologist,0.13513513513513514,0.39729102720845005,GHCEA
Policy intervention to reduce sodium consumption by 10%,1.6129032258064515,15.936040005767003,GHCEA
Policy intervention to reduce sodium consumption by 10%,2.1739130434782608,23.029703379639066,GHCEA
Policy intervention to reduce sodium consumption by 10%,0.12987012987012986,1.1889256108200186,GHCEA
Policy intervention to reduce sodium consumption by 10%,0.2127659574468085,2.1942784101410306,GHCEA
Community health workerss received training to implement the community case management of severe acute malnutrition,34.48275862068965,798.5549646889847,GHCEA
Neonatal care package- 2 antenatal home visits by community health workers followed by 3 postnatal home visits,8.333333333333334,39.640355655943644,GHCEA
Policy intervention to reduce sodium consumption by 10%,5.263157894736842,49.10256193131555,GHCEA
"Community-based interventions for maternal and newborn health (e.g. pregnancy surveillance, birth preparedness, essential newborn care training, referral and/or home treatment for sepsis)",8.333333333333334,39.640355655943644,GHCEA
Inpatient treatment for severe acute malnutrition,4.166666666666667,23.281485850990805,GHCEA
Policy intervention to reduce sodium consumption by 10%,0.19607843137254902,1.957607212836177,GHCEA
Policy intervention to reduce sodium consumption by 10%,7.6923076923076925,240.0946977417272,GHCEA
Policy intervention to reduce sodium consumption by 10%,1.2820512820512822,13.110838718870832,GHCEA
Policy intervention to reduce sodium consumption by 10%,0.1282051282051282,1.1670241758161075,GHCEA
Antivenom for snakebite,11.627906976744185,39.20635136925494,GHCEA
Quadrivalent conjugate meningococcal vaccine,1.492537313432836,10.10829069226563,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),6.25,29.576109803295726,GHCEA
Policy intervention to reduce sodium consumption by 10%,6.666666666666667,60.38222795379846,GHCEA
Policy intervention to reduce sodium consumption by 10%,1.4492753623188406,13.770563281410325,GHCEA
Policy intervention to reduce sodium consumption by 10%,3.8461538461538463,36.6410463746437,GHCEA
Policy intervention to reduce sodium consumption by 10%,1.5384615384615385,15.490881953229577,GHCEA
Policy intervention to reduce sodium consumption by 10%,1.1111111111111112,8.901515602374147,GHCEA
Xpert MTB/RIF automated DNA test to detect tuberculosis and rifampicin (RIF) resistance,0.7142857142857143,5.291948076136413,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,19.230769230769234,8.775329282296536,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),0.10869565217391305,0.420292086678413,GHCEA
Cochlear implant,0.02380952380952381,0.22221587396732653,GHCEA
"Tuberculosis culture using the solid media, 24 patients/week",2.0,8.468239286203442,GHCEA
Rotarix vaccine,0.5,0.8726003490401396,GHCEA
"Tuberculosis culture using the solid media, 8 patients/week",0.8333333333333334,3.674896294012815,GHCEA
Policy intervention to reduce sodium consumption by 10%,8.333333333333334,85.34305489889759,GHCEA
Tuberculin skin test (TST) followed by isoniazid preventive therapy (IPT) for positive TST (no evidence of active tuberculosis),0.3448275862068965,5.889048412160653,GHCEA
Visit the health center three times weekly during the first 2 months (of tuberculosis treatment) of intensive treatment and twice weekly thereafter for supervised medication intake,9.09090909090909,307.1365248803788,GHCEA
Policy intervention to reduce sodium consumption by 10%,0.0909090909090909,0.9036074649574758,GHCEA
Policy intervention to reduce sodium consumption by 10%,5.555555555555555,56.29970140221268,GHCEA
Antivenom for snakebite,10.0,23.695289893148118,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),3.4482758620689653,26.618498822966156,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,50.0,52.523421864042035,GHCEA
Policy intervention to reduce sodium consumption by 10%,10.0,87.75329282296535,GHCEA
Quadrivalent conjugate meningococcal vaccine,1.3888888888888888,9.8223242889174,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,142.85714285714286,565.3991883011585,GHCEA
Quadrivalent conjugate meningococcal vaccine,1.2987012987012987,8.266614541293837,GHCEA
Policy intervention to reduce sodium consumption by 10%,5.0,27.275846729138394,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),2.7777777777777777,21.81844165816898,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,71.42857142857143,139.30124929158976,GHCEA
Policy intervention to reduce sodium consumption by 10%,0.625,5.800795890609566,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),1.6129032258064515,4.300242136181932,GHCEA
Policy intervention to reduce sodium consumption by 10%,18.867924528301884,199.88860192465197,GHCEA
Antivenom for snakebite,11.11111111111111,39.53633848346295,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,43.47826086956522,118.66402717431721,GHCEA
Quadrivalent conjugate meningococcal vaccine,1.36986301369863,9.307167420617537,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),5.263157894736842,11.294978284144054,GHCEA
Policy intervention to reduce sodium consumption by 10%,4.166666666666667,32.726321244579516,GHCEA
Policy intervention to reduce sodium consumption by 10%,1.9230769230769231,19.264105485465098,GHCEA
Quadrivalent conjugate meningococcal vaccine,1.2345679012345678,8.853159253758145,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),4.0,19.01321344497583,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,125.0,686.5561572228353,GHCEA
Policy intervention to reduce sodium consumption by 10%,10.526315789473683,100.59901293638003,GHCEA
Policy intervention to reduce sodium consumption by 10%,5.88235294117647,51.4168414583082,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),3.225806451612903,19.864551360422503,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,200.0,961.1786201119693,GHCEA
Antivenom for snakebite,7.142857142857142,12.221158897630692,GHCEA
Quadrivalent conjugate meningococcal vaccine,1.2658227848101267,9.033427202364082,GHCEA
Fortification of wheat flour with folic acid to prevent spina bifida,8.333333333333334,362.97952940408396,GHCEA
Rotarix vaccine,0.07142857142857144,1.325622451342936,GHCEA
Policy intervention to reduce sodium consumption by 10%,2.5,23.544386729043982,GHCEA
Human papilloma virus (HPV) vaccine; 70% coverage,0.00625,0.06341462165787723,GHCEA
Pap smear screening every 5 years,0.03125,0.793003937129081,GHCEA
Hybrid Benefit-based tailored treatment and Treat-to-target strategy to reduce cardiovascular disease,2.2222222222222223,101.21102214055571,GHCEA
Universal hearing screening using otoacoustic emission (OAE),0.03125,0.29576109803295725,GHCEA
Targeted hearing screening using otoacoustic emission (OAE) and automated auditory brainstem response (AABR),0.04545454545454545,0.5703964033492748,GHCEA
Policy intervention to reduce sodium consumption by 10%,8.333333333333334,99.16241955656088,GHCEA
Clinical assessment,0.1282051282051282,1.2711795044396446,GHCEA
Benefit-based tailored treatment,0.13513513513513514,172.10236307952258,GHCEA
"Comprehensive programme included screening of all patients with sputum-smear-positive pulmonary tuberculosis, rapid diagnosis, standardized care and financial protection against catastrophic health expenditure",16.666666666666668,6.599627807346981,GHCEA
Target-to-treat,0.0909090909090909,49.538149174254634,GHCEA
Universal hearing screening using otoacoustic emission (OAE) and automated auditory brainstem response (AABR),0.024390243902439025,0.18571045690441504,GHCEA
Pulse oximetry + clinical assessment,0.01694915254237288,0.4573101389812076,GHCEA
Colonoscopy screening every 10 years,0.012987012987012988,0.96420546328059,GHCEA
Hybrid Benefit-based tailored treatment and Treat-to-target intensive strategy to reduce cardiovascular disease,2.2222222222222223,33.14881547069259,GHCEA
Treat-to-target Intensive strategy to reduce cardiovascular disease,2.2222222222222223,108.79495431730034,GHCEA
Benefit-based tailored treatment Intensive Strategy to reduce cardiovascular disease,3.571428571428571,71.29955041865934,GHCEA
Benefit-based tailored treatment to reduce incidence of cardiovascular disease,3.4482758620689653,111.21935441350762,GHCEA
Health X project for national tuberculosis control,6.25,43.876646411482675,GHCEA
Targeted hearing screening using otoacoustic emission (OAE),0.06666666666666667,0.8872832940988719,GHCEA
Treat-to-target strategy to reduce incidence of cardiovascular disease,2.2222222222222223,88.33572618240981,GHCEA
Pentavalent antimony,0.05,0.8581076345250211,GHCEA
Cochlear implant,0.01,0.3641381507929706,GHCEA
Policy intervention to reduce sodium consumption by 10%,6.25,69.52420030375977,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,142.85714285714286,686.5561572228353,GHCEA
Policy intervention to reduce sodium consumption by 10%,0.35714285714285715,2.077676504979796,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),1.0101010101010102,0.6694232246533528,GHCEA
Quadrivalent conjugate meningococcal vaccine,1.2658227848101267,8.804354627221441,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,142.85714285714286,686.5561572228353,GHCEA
Policy intervention to reduce sodium consumption by 10%,3.571428571428571,26.085485404533518,GHCEA
Policy intervention to reduce sodium consumption by 10%,12.195121951219512,100.7513202988878,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),6.25,41.375904906165005,GHCEA
Long-lasting insecticide-treated bed nets (ITNs) + information on correct use and malaria transmission,45.45454545454545,9.701797651427343,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),5.555555555555555,13.887912429373648,GHCEA
Policy intervention to reduce sodium consumption by 10%,1.2820512820512822,12.115839245774307,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,38.46153846153847,961.1786201119693,GHCEA
Policy intervention to reduce sodium consumption by 10%,11.363636363636363,97.65867245799005,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),3.3333333333333335,10.864693397129043,GHCEA
Antivenom for snakebite,7.6923076923076925,19.45607067266798,GHCEA
Quadrivalent conjugate meningococcal vaccine,1.3333333333333333,9.495302790594346,GHCEA
Policy intervention to reduce sodium consumption by 10%,3.7037037037037037,35.775949316293385,GHCEA
Policy intervention to reduce sodium consumption by 10%,4.3478260869565215,39.73898804125328,GHCEA
Policy intervention to reduce sodium consumption by 10%,0.3225806451612903,3.334425794565843,GHCEA
Policy intervention to reduce sodium consumption by 10%,4.166666666666667,43.667904231912544,GHCEA
Increased minimum legal drinking age to reduce alcohol consumption,0.11111111111111112,5.7866301789056855,GHCEA
Longer individual intervention by telephone for alcohol misuse/abuse,0.01,0.313466129416677,GHCEA
Policy intervention to reduce sodium consumption by 10%,1.1111111111111112,11.160484188967251,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,66.66666666666667,961.1786201119693,GHCEA
Policy intervention to reduce sodium consumption by 10%,1.0,7.758761061074635,GHCEA
Policy intervention to reduce sodium consumption by 10%,0.06666666666666667,0.5999062187542377,GHCEA
Rotarix vaccine,1.6666666666666667,2.336448598130841,GHCEA
Policy intervention to reduce sodium consumption by 10%,4.761904761904763,41.04203960985685,GHCEA
"Enhanced regulatory system was established based on governmental policies requiring condom use between sex workers and clients, for which violations could result in fines and closures of sex establishments",1.7543859649122808,6.860437840970659,GHCEA
Cochlear implant,0.005555555555555556,0.33337019482716235,GHCEA
Tension-free inguinal hernia repair surgery with mosquito net meesh,9.09090909090909,636.8061919369894,GHCEA
Policy intervention to reduce sodium consumption by 10%,3.125,27.575363952104173,GHCEA
Policy intervention to reduce sodium consumption by 10%,17.543859649122805,170.55851445727993,GHCEA
Policy intervention to reduce sodium consumption by 10%,2.2727272727272725,20.30344930688222,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,250.0,1373.1123144456706,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),6.666666666666667,35.491331763954875,GHCEA
Policy intervention to reduce sodium consumption by 10%,0.19607843137254902,1.4621371269179222,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),0.07692307692307693,65.45532497450695,GHCEA
Quadrivalent conjugate meningococcal vaccine,1.6666666666666667,10.264202630963812,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,90.9090909090909,152.5680349384078,GHCEA
Policy intervention to reduce sodium consumption by 10%,4.545454545454545,36.60074088775252,GHCEA
Policy intervention to reduce sodium consumption by 10%,0.625,6.418684559154615,GHCEA
Multidrug-resistant treatment as per WHO guidelines,1.2987012987012987,13.199255614693962,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,111.1111111111111,331.440903486886,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),0.08333333333333333,72.59590588081679,GHCEA
Quadrivalent conjugate meningococcal vaccine,1.492537313432836,9.774234573916582,GHCEA
Policy intervention to reduce sodium consumption by 10%,8.333333333333334,66.66847259049798,GHCEA
Policy intervention to reduce sodium consumption by 10%,2.2727272727272725,18.800145133463243,GHCEA
Policy intervention to reduce sodium consumption by 10%,1.4705882352941175,15.364508498268071,GHCEA
Policy intervention to reduce sodium consumption by 10%,1.9230769230769231,19.68387105151679,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,200.0,961.1786201119693,GHCEA
"Intermittent preventive treatment in infants (IPTi) using sulfadoxine pyrimethamine (SP) against clinical malaria; at 2, 3, and 9 months.",20.0,20.324119128782286,GHCEA
Policy intervention to reduce sodium consumption by 10%,0.7692307692307693,4.882575356394202,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),6.25,9.013035718837298,GHCEA
Community-based screening and early treatment with antiviral therapy for hepatitis B virus,1.7543859649122808,475.3303361243956,GHCEA
Antivenom for snakebite,6.25,34.22720692164865,GHCEA
Quadrivalent conjugate meningococcal vaccine,1.5625,10.185650059808479,GHCEA
Policy intervention to reduce sodium consumption by 10%,2.5,22.539585218013055,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),4.0,13.091064994901389,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,250.0,1201.4732751399617,GHCEA
Policy intervention to reduce sodium consumption by 10%,15.625,172.9971760591388,GHCEA
Policy intervention to reduce sodium consumption by 10%,3.125,30.539810489864795,GHCEA
Quadrivalent conjugate meningococcal vaccine,1.7543859649122808,11.640742925495402,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),4.545454545454545,16.26384856800376,GHCEA
"Intermittent preventive treatment in infants (IPTi) using sulfadoxine pyrimethamine (SP) against clinical malaria; at 3, 9, and 15 months.",250.0,1786.4764310715543,GHCEA
Policy intervention to reduce sodium consumption by 10%,9.09090909090909,71.28045743898818,GHCEA
Individual donation Nucleic acid amplification testing (ID-NAT) to the HIV antibody screening for HIV screenig of blood donations,0.2173913043478261,4.661733594214738,GHCEA
Mini pool nucleic acid amplification testing (MPNAT) for HIV screenig of blood donations,0.3448275862068965,5.229567548716337,GHCEA
"Intermittent preventive treatment in infants (IPTi) using sulfadoxine pyrimethamine (SP) against clinical malaria; at 3, 9, and 15 months.",333.3333333333333,2001.3908889448235,GHCEA
"Low-dose, high-frequency (LDHF) training for basic emergency obstetric and newborn care",18.18181818181818,96.68906219747967,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,142.85714285714286,686.5561572228353,GHCEA
Adding p24 antigen for HIV screening of blood donations,0.625,2.039210839348786,GHCEA
Quality improvement program to reduce maternal and fetal mortality,6.25,120.99317646802798,GHCEA
Target-to-treat,0.058823529411764705,10.411407623063687,GHCEA
Benefit-based tailored treatment,0.08333333333333333,62.38710661632693,GHCEA
"Intermittent preventive treatment in infants (IPTi) using sulfadoxine pyrimethamine (SP) against clinical malaria; at 3, 4, 9 and 12 months.",250.0,2123.816395449427,GHCEA
Antivenom for snakebite,9.09090909090909,24.137924755583978,GHCEA
Policy intervention to reduce sodium consumption by 10%,2.631578947368421,25.58978929337258,GHCEA
Policy intervention to reduce sodium consumption by 10%,0.1,0.8549408805862925,GHCEA
Policy intervention to reduce sodium consumption by 10%,2.631578947368421,23.56731686604252,GHCEA
Cochlear implant,0.00625,0.24989202800381297,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),6.666666666666667,36.29795294040839,GHCEA
Policy intervention to reduce sodium consumption by 10%,7.6923076923076925,67.8351142277425,GHCEA
Quadrivalent conjugate meningococcal vaccine,1.4084507042253522,9.043657584246713,GHCEA
Antivenom for snakebite,11.627906976744185,39.975719097366074,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,200.0,798.5549646889847,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),2.5,8.756085139133603,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,47.61904761904761,15.416119009439859,GHCEA
Quadrivalent conjugate meningococcal vaccine,1.3513513513513513,8.775329282296536,GHCEA
Policy intervention to reduce sodium consumption by 10%,5.0,42.03584590666866,GHCEA
Policy intervention to reduce sodium consumption by 10%,1.694915254237288,13.826833893565547,GHCEA
SGOT/SGPT (serum glutamic oxaloacetic transaminase/serum glutamic pyruvic transaminase) test conducted at baseline (asymptomatic),0.05,0.11772887582028374,GHCEA
Creatinine test conducted at baseline (asymptomatic),0.005263157894736842,0.012385881914739265,GHCEA
Policy intervention to reduce sodium consumption by 10%,11.235955056179774,100.70049996077991,GHCEA
"Complete blood count (CBC - hemoglobin, neutrophils, and platelets) test conducted at baseline (asymptomatic)",0.6666666666666666,7.922172268739927,GHCEA
Rotarix vaccine,2.7777777777777777,3.7313432835820897,GHCEA
Policy intervention to reduce sodium consumption by 10%,4.0,36.42876532498447,GHCEA
Policy intervention to reduce sodium consumption by 10%,2.2727272727272725,24.410190275997575,GHCEA
Policy intervention to reduce sodium consumption by 10%,0.0909090909090909,2.8694961917165296,GHCEA
Composite programs for HIV prevention,6.25,0.42733181606945186,GHCEA
Aspirin + beta blockers + angiotensin-converting enzyme inhibitors (ACEI) for prevention of acute myocardial infarction,0.3225806451612903,0.9053911164274203,GHCEA
"Avahan HIV prevention programme- peer-led outreach, education and condom distribution, free treatment of sexually transmitted infections (STIs), free commodity supplies (condoms, STI drugs), and facilitation of community mobilization",20.0,420.29208667841294,GHCEA
"Avahan HIV prevention programme- peer-led outreach, education and condom distribution, free treatment of sexually transmitted infections (STIs), free commodity supplies (condoms, STI drugs), and facilitation of community mobilization",1.9607843137254901,2.4428111492474294,GHCEA
Migrant Labourer Program for HIV prevention,10.0,1.1272656192673414,GHCEA
Rotavirus vaccination,3.225806451612903,16.533229082587674,GHCEA
"Avahan HIV prevention programme- peer-led outreach, education and condom distribution, free treatment of sexually transmitted infections (STIs), free commodity supplies (condoms, STI drugs), and facilitation of community mobilization",21.27659574468085,156.57940484097742,GHCEA
Rotavirus vaccination,9.09090909090909,53.59429293214662,GHCEA
Increase in rotavirus immunization coverage to 90% through targeted increases in rural and urban regions,25.64102564102564,137.65815629873896,GHCEA
Aspirin + beta blockers + angiotensin-converting enzyme inhibitors (ACEI) + statin for prevention of acute myocardial infarction,0.136986301369863,0.5158623802900417,GHCEA
"Avahan HIV prevention programme- peer-led outreach, education and condom distribution, free treatment of sexually transmitted infections (STIs), free commodity supplies (condoms, STI drugs), and facilitation of community mobilization",10.0,65.45532497450695,GHCEA
Rotavirus vaccination,8.333333333333334,48.105720764396665,GHCEA
Program to increase coverage of tertiary treatment of cardiovascular disease with increased access to tertiary treatment,0.4347826086956522,5.288443474761489,GHCEA
Aspirin + injection streptokinase (1 dose at 1.5 mU),1.4492753623188406,9.285522845220752,GHCEA
Hybrid Benefit-based tailored treatment and Treat-to-target strategy to reduce cardiovascular disease (CVD),2.7027027027027026,128.3850425544991,GHCEA
"Avahan HIV prevention programme- peer-led outreach, education and condom distribution, free treatment of sexually transmitted infections (STIs), free commodity supplies (condoms, STI drugs), and facilitation of community mobilization",52.63157894736842,257.59837570612405,GHCEA
Aspirin + beta blockers for prevention of acute myocardial infarction,0.5,2.4169339124969267,GHCEA
Aspirin alone for prevention of acute myocardial infarction,3.3333333333333335,18.701521421287698,GHCEA
Isoniazid preventive therapy therapy for all HIV+ pregnant women regardless of CD4 count,5.555555555555555,6.209603146881685,GHCEA
Target-to-treat,0.06666666666666667,13.655180654736402,GHCEA
"Avahan HIV prevention programme- peer-led outreach, education and condom distribution, free treatment of sexually transmitted infections (STIs), free commodity supplies (condoms, STI drugs), and facilitation of community mobilization",10.416666666666666,44.11905882259584,GHCEA
"Avahan HIV prevention programme- peer-led outreach, education and condom distribution, free treatment of sexually transmitted infections (STIs), free commodity supplies (condoms, STI drugs), and facilitation of community mobilization",31.25,122.85460995215149,GHCEA
"Avahan HIV prevention programme- peer-led outreach, education and condom distribution, free treatment of sexually transmitted infections (STIs), free commodity supplies (condoms, STI drugs), and facilitation of community mobilization",18.867924528301884,221.82082352471792,GHCEA
"Avahan HIV prevention programme- peer-led outreach, education and condom distribution, free treatment of sexually transmitted infections (STIs), free commodity supplies (condoms, STI drugs), and facilitation of community mobilization",50.0,319.42198587559386,GHCEA
"Avahan HIV prevention programme- peer-led outreach, education and condom distribution, free treatment of sexually transmitted infections (STIs), free commodity supplies (condoms, STI drugs), and facilitation of community mobilization",34.48275862068965,285.19820167463735,GHCEA
Genetically modified (GM) fortification of mustard oil with genetically modified mustard seed,1.9607843137254901,275.36378092723606,GHCEA
"Avahan HIV prevention programme- peer-led outreach, education and condom distribution, free treatment of sexually transmitted infections (STIs), free commodity supplies (condoms, STI drugs), and facilitation of community mobilization",41.666666666666664,159.71099293779693,GHCEA
Aspirin alone (325 mg initial dose & subsequently 75 mg doses once daily,1000.0,12879.918785306205,GHCEA
Benefit-based tailored treatment to reduce cardiovascular disease,4.545454545454545,144.66575447264213,GHCEA
Rotavirus vaccination,10.0,52.193134946992465,GHCEA
Rotavirus vaccination,10.0,58.28868355394049,GHCEA
High-dose vitamin A supplementation,34.48275862068965,3992.7748234449236,GHCEA
Rotavirus vaccination,5.88235294117647,26.35494932966946,GHCEA
Gestational diabetes mellitus screening using oral glucose tolerance test (OGTT),0.5555555555555556,2.3390596505242667,GHCEA
Program to increase coverage of primary prevention of cardiovascular disease with increased access to treatment,2.0408163265306123,30.134149610905084,GHCEA
"Rotavirus vaccine introduced at the current DPT3 (diphtheria, pertussis, tetanus) immunization coverage level",13.333333333333334,425.44217617953365,GHCEA
Rotavirus vaccination,6.666666666666667,34.27274526562166,GHCEA
Program to increase coverage of primary prevention and tertiary treatment of cardiovascular disease with increased access to primary prevention and tertiary treatment,0.4347826086956522,1330.9249411483077,GHCEA
Benefit-based tailored treatment,0.0909090909090909,71.04581536378865,GHCEA
Supplementary immunization activity (SIA) for measles,83.33333333333333,39.144851210244354,GHCEA
"Avahan HIV prevention programme- peer-led outreach, education and condom distribution, free treatment of sexually transmitted infections (STIs), free commodity supplies (condoms, STI drugs), and facilitation of community mobilization",16.393442622950822,93.94764290458643,GHCEA
"Avahan HIV prevention programme- peer-led outreach, education and condom distribution, free treatment of sexually transmitted infections (STIs), free commodity supplies (condoms, STI drugs), and facilitation of community mobilization",30.303030303030305,117.43455363073302,GHCEA
Benefit-based tailored treatment and treat-to-target intensive strategy combined to reduce cardiovascular disease,2.7027027027027026,14.471818859894613,GHCEA
"Avahan HIV prevention programme- peer-led outreach, education and condom distribution, free treatment of sexually transmitted infections (STIs), free commodity supplies (condoms, STI drugs), and facilitation of community mobilization",52.63157894736842,210.14604333920647,GHCEA
"Polypill (combining aspirin, beta blockers, angiotensin-converting enzyme inhibitors and statins) for prevention of acute myocardial infarction",0.5263157894736842,2.5017386111810294,GHCEA
Treat-to-target Intensive strategy to reduce cardiovascular disease,2.3809523809523814,36.31445951291426,GHCEA
Policy intervention to reduce sodium consumption by 10%,9.09090909090909,91.75628687682232,GHCEA
Treat-to-target strategy to reduce cardiovascular disease,2.4390243902439024,85.40694809507858,GHCEA
Program to increase coverage of primary and secondary prevention of cardiovascular disease with increased access to primary and secondary treatment,0.4,532.3699764593232,GHCEA
Isoniazid preventive therapy therapy for all HIV+ pregnant women with CD4 count <= 200 cells/ul,4.761904761904763,44.86263846567329,GHCEA
"Avahan HIV prevention programme- peer-led outreach, education and condom distribution, free treatment of sexually transmitted infections (STIs), free commodity supplies (condoms, STI drugs), and facilitation of community mobilization",9.09090909090909,9.495302790594346,GHCEA
"Program to increase coverage of primary, secondary and tertiary treatment of cardiovascular disease with increased access to secondary and tertiary treatment",0.17241379310344826,1.8412611590707508,GHCEA
"Avahan HIV prevention programme- peer-led outreach, education and condom distribution, free treatment of sexually transmitted infections (STIs), free commodity supplies (condoms, STI drugs), and facilitation of community mobilization",14.285714285714285,142.59910083731867,GHCEA
"Avahan HIV prevention programme- peer-led outreach, education and condom distribution, free treatment of sexually transmitted infections (STIs), free commodity supplies (condoms, STI drugs), and facilitation of community mobilization",2.5641025641025643,7.562073529251749,GHCEA
"Coverage of 3 doses of rotavirus with DPT (diphtheria, pertussis, tetanus) and 1 dose of the measles vaccine",31.25,114.66900699152566,GHCEA
"Avahan HIV prevention programme- peer-led outreach, education and condom distribution, free treatment of sexually transmitted infections (STIs), free commodity supplies (condoms, STI drugs), and facilitation of community mobilization",10.638297872340425,60.04172666834471,GHCEA
"Avahan HIV prevention programme- peer-led outreach, education and condom distribution, free treatment of sexually transmitted infections (STIs), free commodity supplies (condoms, STI drugs), and facilitation of community mobilization",50.0,532.3699764593232,GHCEA
Program to increase coverage of secondary prevention of cardiovascular disease with increased access to secondary treatment,0.4,13.155765480872894,GHCEA
"Avahan HIV prevention programme- peer-led outreach, education and condom distribution, free treatment of sexually transmitted infections (STIs), free commodity supplies (condoms, STI drugs), and facilitation of community mobilization",2.3255813953488373,3.3190148158311916,GHCEA
Rotavirus vaccination,7.6923076923076925,44.86263846567329,GHCEA
Men who have sex with men (MSM) programs for HIV prevention,83.33333333333333,13.936386818306888,GHCEA
"Avahan HIV prevention programme- peer-led outreach, education and condom distribution, free treatment of sexually transmitted infections (STIs), free commodity supplies (condoms, STI drugs), and facilitation of community mobilization",14.285714285714285,76.05285377990332,GHCEA
"Avahan HIV prevention programme- peer-led outreach, education and condom distribution, free treatment of sexually transmitted infections (STIs), free commodity supplies (condoms, STI drugs), and facilitation of community mobilization",29.41176470588235,156.57940484097742,GHCEA
Benefit-based tailored treatment Intensive Strategy to reduce cardiovascular disease,5.0,137.44491646970476,GHCEA
Rotavirus vaccination,8.333333333333334,56.23626511894258,GHCEA
Policy intervention to reduce sodium consumption by 10%,13.513513513513514,135.23369427417182,GHCEA
Haemophilus influenzae type B (Hib) vaccine,11.904761904761903,380.2642688995164,GHCEA
Yaws eradication program,2.4390243902439024,8.98262052518543,GHCEA
Policy intervention to reduce sodium consumption by 10%,11.76470588235294,113.59245585903054,GHCEA
Policy intervention to reduce sodium consumption by 10%,7.142857142857142,73.03411054408127,GHCEA
Policy intervention to reduce sodium consumption by 10%,1.0,9.703919757558264,GHCEA
Gestational diabetes mellitus screening using oral glucose tolerance test (OGTT),0.5,1.179549430855221,GHCEA
Policy intervention to reduce sodium consumption by 10%,0.9090909090909091,8.583382218401514,GHCEA
Policy intervention to reduce sodium consumption by 10%,3.571428571428571,35.95798652237863,GHCEA
Policy intervention to reduce sodium consumption by 10%,1.0,8.230913168441075,GHCEA
Policy intervention to reduce sodium consumption by 10%,3.4482758620689653,39.329933249063465,GHCEA
Policy intervention to reduce sodium consumption by 10%,3.4482758620689653,34.90492895746939,GHCEA
Policy intervention to reduce sodium consumption by 10%,7.142857142857142,85.1247164149861,GHCEA
Post exposure prophylaxis (PEP) for prevention of Rabies infection,0.8333333333333334,3.901098997015069,GHCEA
Assisted partner services intervention for HIV testing,1.1627906976744187,13.398573233036656,GHCEA
Pneumococcal vaccination (PCV10),15.151515151515152,103.70843697259542,GHCEA
Assisted partner services intervention for HIV testing,0.9090909090909091,10.03209754634403,GHCEA
Cochlear implants,0.10752688172043011,3.077283100920943,GHCEA
Policy intervention to reduce sodium consumption by 10%,0.5263157894736842,2.839659921017672,GHCEA
Quadrivalent conjugate meningococcal vaccine,1.4705882352941175,9.450354611703961,GHCEA
Providing long-lasting insecticide-treated nets (LLINs) and point-of-use water filters to delay HIV-1 progression,9.09090909090909,37.31565255556003,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,100.0,310.0576193909578,GHCEA
"Intermittent preventive treatment in infants (IPTi) using 3 days of amodiaquine-artesunate (AQ3-AS3) against clinical malaria; at 2, 3, and 9 months.",111.1111111111111,531.6610949993241,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),2.631578947368421,15.844344537479854,GHCEA
Haemophilus influenzae type b (Hib) vaccine,20.408163265306122,215.82566613215803,GHCEA
"Intermittent preventive treatment in infants (IPTi) using sulfadoxine pyrimethamine plus 3 days of artesunate (SP-AS3) against clinical malaria; at 2, 3, and 9 months.",71.42857142857143,264.6851059625405,GHCEA
Pneumococcal vaccination (PCV13),18.867924528301884,126.75475629983883,GHCEA
"Intermittent preventive treatment in infants (IPTi) using 3 days of chlorproguanil-dapsone (CD3) against clinical malaria; at 2, 3, and 9 months.",12.5,11.235068512866112,GHCEA
Policy intervention to reduce sodium consumption by 10%,0.0909090909090909,0.6987258992810089,GHCEA
Policy intervention to reduce sodium consumption by 10%,27.027027027027028,264.42217373807443,GHCEA
Policy intervention to reduce sodium consumption by 10%,4.545454545454545,51.47981979686595,GHCEA
Policy intervention to reduce sodium consumption by 10%,0.3225806451612903,2.8249033008199427,GHCEA
Policy intervention to reduce sodium consumption by 10%,21.27659574468085,230.39670071811446,GHCEA
Policy intervention to reduce sodium consumption by 10%,13.157894736842104,131.34127708700404,GHCEA
Policy intervention to reduce sodium consumption by 10%,1.639344262295082,16.828334661433097,GHCEA
Policy intervention to reduce sodium consumption by 10%,1.8518518518518519,18.27273270534494,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,71.42857142857143,181.35445662489985,GHCEA
Xpert MTB/RIF automated DNA test to detect tuberculosis and rifampicin (RIF) resistance,0.9090909090909091,4.152651922459619,GHCEA
Policy intervention to reduce sodium consumption by 10%,5.263157894736842,43.37144061964939,GHCEA
Policy intervention to reduce sodium consumption by 10%,5.88235294117647,48.280227611184074,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,500.0,2402.9465502799235,GHCEA
Antivenom for snakebite,3.7037037037037037,29.575014432390827,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),2.7777777777777777,10.133946252398282,GHCEA
Policy intervention to reduce sodium consumption by 10%,3.4482758620689653,32.004928246923356,GHCEA
Policy intervention to reduce sodium consumption by 10%,1.0,9.751080234070686,GHCEA
Policy intervention to reduce sodium consumption by 10%,0.13333333333333333,1.4180272659598943,GHCEA
Policy intervention to reduce sodium consumption by 10%,5.555555555555555,59.15221960659145,GHCEA
Policy intervention to reduce sodium consumption by 10%,10.638297872340425,80.25678037075224,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),3.7037037037037037,23.6258865292599,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,333.3333333333333,1373.1123144456706,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),2.2222222222222223,7.612535411715774,GHCEA
Cochlear implant,0.12987012987012986,3.9260322747737697,GHCEA
Policy intervention to reduce sodium consumption by 10%,2.7027027027027026,16.918178951483753,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,142.85714285714286,213.59524891377097,GHCEA
Policy intervention to reduce sodium consumption by 10%,6.25,62.86349403203846,GHCEA
Policy intervention to reduce sodium consumption by 10%,0.17241379310344826,1.640147397077277,GHCEA
Antivenom for snakebite,5.88235294117647,35.55137408463114,GHCEA
Policy intervention to reduce sodium consumption by 10%,9.09090909090909,74.82010350313732,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),3.4482758620689653,18.745421706314197,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,100.0,961.1786201119693,GHCEA
Quadrivalent conjugate meningococcal vaccine,1.3888888888888888,9.296332534214024,GHCEA
Policy intervention to reduce sodium consumption by 10%,0.2702702702702703,2.7950625641017024,GHCEA
Policy intervention to reduce sodium consumption by 10%,0.0625,0.5174629050895047,GHCEA
Quadrivalent conjugate meningococcal vaccine,1.6129032258064515,10.159732375177922,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),3.125,7.5692413714595705,GHCEA
Policy intervention to reduce sodium consumption by 10%,5.0,46.30646359460624,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,142.85714285714286,640.785746741313,GHCEA
Policy intervention to reduce sodium consumption by 10%,3.8461538461538463,51.45991523965619,GHCEA
Policy intervention to reduce sodium consumption by 10%,3.125,29.323062633165083,GHCEA
Rotarix vaccine,0.35714285714285715,7.89085933487139,GHCEA
Benefit-based tailored treatment,0.1234567901234568,64.97599387217127,GHCEA
Target-to-treat,0.0909090909090909,48.39727058721119,GHCEA
Policy intervention to reduce sodium consumption by 10%,0.15625,1.368482955872221,GHCEA
Policy intervention to reduce sodium consumption by 10%,10.869565217391305,111.31237310969959,GHCEA
Mass vaccination of livestock against brucellosis,37.03703703703704,16.584734469137793,GHCEA
Policy intervention to reduce sodium consumption by 10%,15.873015873015872,163.10354670935146,GHCEA
Policy intervention to reduce sodium consumption by 10%,0.38461538461538464,3.9629142644622006,GHCEA
Policy intervention to reduce sodium consumption by 10%,9.09090909090909,99.64499185038491,GHCEA
Preventive treatment of malaria in pregnancy with sulphadoxine-pyrimethamine (IPTp-SP) combined with insectiside treated mosquito nets on neonatal survival,1000.0,2618.2129989802775,GHCEA
Policy intervention to reduce sodium consumption by 10%,5.555555555555555,43.76123217278523,GHCEA
Preventive treatment of malaria in pregnancy with sulphadoxine-pyrimethamine (IPTp-SP) combined with insectiside treated mosquito nets on clinical malaria,20.408163265306122,104.79723946049668,GHCEA
"Intermittent preventive treatment in infants (IPTi) using sulfadoxine pyrimethamine (SP) against clinical malaria; at 3, 4, and 9 months.",125.0,476.46477606741325,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),1.5625,5.109116856615385,GHCEA
Preventive treatment of malaria in pregnancy with sulphadoxine-pyrimethamine (IPTp-SP) combined with insectiside treated mosquito nets on combined clinical malaria and neonatal mortality,1000.0,104.79723946049668,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,250.0,998.1937058612309,GHCEA
"RTS,S/AS01 malaria vaccine",5.0,0.35697584474250543,GHCEA
Oral rehydration salts and zinc treatment included in social franchising program,4.166666666666667,49.90968529306154,GHCEA
Policy intervention to reduce sodium consumption by 10%,29.41176470588235,314.88760437262806,GHCEA
"Pre-erythrocytic RTS, S malaria vaccination",13.888888888888888,43.51798172692014,GHCEA
Increasing coverage of valve surgery (VS) by refering for surgery abroad,0.23255813953488375,5.248954650371935,GHCEA
Increasing coverage of valve surgery (VS) by building surgical center,0.037037037037037035,1.4858716352747598,GHCEA
Orthopaedic Trauma Care Specialist (OTCS) program,6.666666666666667,115.0324063222392,GHCEA
Preventive chemotherapy treatment of Lymphatic Filariasis,15.151515151515152,120.99317646802798,GHCEA
Scaling up secondary prevention (SP) services: creating and maintaining a registry of individuals with a history of acute rheumatic fever (ARF) or Rheumatic heart disease (RHD) who then receive prophylactic penicillin on a regular basis.,1.176470588235294,0.37791060565600465,GHCEA
"Prereferral rectal artesunate, low intervention uptake (25%), low referral compliance (25%)",1.0,32.330160513724074,GHCEA
Scaling up primary prevention (PP) services: improving treatment of pharyngitis in primary care settings.,0.3448275862068965,8.414787981843693,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),0.5,0.7054995712421457,GHCEA
Xpert MTB/RIF automated DNA test to detect tuberculosis and rifampicin (RIF) resistance,1.0416666666666667,7.883069740266383,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,38.46153846153847,58.25324970375572,GHCEA
Policy intervention to reduce sodium consumption by 10%,3.0303030303030303,26.94725533809087,GHCEA
Policy intervention to reduce sodium consumption by 10%,11.494252873563218,110.14551237089444,GHCEA
Magnesium sulfate + calcium,55.55555555555555,3131.5880968195484,GHCEA
Magnesium sulfate + calcium during antenatal care for pre-eclampsia/eclampsia,38.46153846153847,1865.7826277780016,GHCEA
Magnesium sulfate,250.0,5703.964033492748,GHCEA
"Bacille Calmette Guerin (BCG) vaccination against tuberculosis, in current extended group",0.11627906976744187,0.631368567907167,GHCEA
School gruiten intervention that focused on free fruit and vegetable provisions and encouraged nutrition curriculum. Included neither family nor computer feedback tools.,0.0625,0.06710545921756172,GHCEA
Policy intervention to reduce sodium consumption by 10%,1.3888888888888888,14.08212327735526,GHCEA
"Bacille Calmette Guerin (BCG) vaccination against tuberculosis, in current target group",0.14285714285714288,0.0687638822603104,GHCEA
Policy intervention to reduce sodium consumption by 10%,1.0,9.71371704666137,GHCEA
Rotavirus vaccination,14.084507042253522,173.5989053671706,GHCEA
Policy intervention to reduce sodium consumption by 10%,3.571428571428571,34.632447076458696,GHCEA
Antivenom for snakebite,10.0,27.71028401308157,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,50.0,66.28818069737719,GHCEA
Quadrivalent conjugate meningococcal vaccine,1.4084507042253522,9.774234573916582,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),4.761904761904763,13.243034240281668,GHCEA
Policy intervention to reduce sodium consumption by 10%,8.333333333333334,67.67414954991396,GHCEA
Policy intervention to reduce sodium consumption by 10%,6.25,55.61355001664354,GHCEA
Quadrivalent conjugate meningococcal vaccine,1.3333333333333333,9.484025708895304,GHCEA
Antivenom for snakebite,10.416666666666666,39.46209550746118,GHCEA
"State-wide health insurance program includes comprehensive health care, increase to antenatal care (ANC), delivery care, essential obstetric care (EOC) to reduce maternal mortality",20.0,61.238877660198206,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,90.9090909090909,369.6840846584498,GHCEA
Cochlear implant,0.08333333333333333,2.332909625150408,GHCEA
Burns management,1.8518518518518519,26.892805438438227,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),6.25,15.596776654081733,GHCEA
Policy intervention to reduce sodium consumption by 10%,0.8333333333333334,8.097292280358797,GHCEA
Policy intervention to reduce sodium consumption by 10%,0.47619047619047616,4.228066737380127,GHCEA
National rotavirus vaccination,6.25,35.489754441535254,GHCEA
"Children given DTP (diphtheria, tetanus, and pertussis) Vaccine at 6, 10, and 14 weeks; pregnant women receive tetanus shot at first contact with health system and 2nd dose 4 weeks after",200.0,2016.5529411337998,GHCEA
Policy intervention to reduce sodium consumption by 10%,7.142857142857142,67.748788045218,GHCEA
Policy intervention to reduce sodium consumption by 10%,2.0833333333333335,20.58184398280844,GHCEA
Rotarix vaccine,0.588235294117647,11.523159663621714,GHCEA
Policy intervention to reduce sodium consumption by 10%,4.3478260869565215,32.07048050959777,GHCEA
Cochlear implant,0.008333333333333333,0.1824309425191293,GHCEA
Policy intervention to reduce sodium consumption by 10%,5.88235294117647,64.6917502178374,GHCEA
Policy intervention to reduce sodium consumption by 10%,2.857142857142857,26.461493958810554,GHCEA
Policy intervention to reduce sodium consumption by 10%,15.151515151515152,156.9486958901306,GHCEA
DOTS-Plus project- chronic cases of MDR-TB referred from public or private facilities and cases with a diagnosis of MDR-TB during treatment with the first-line retreatment regimen,4.761904761904763,23.41803415510219,GHCEA
Policy intervention to reduce sodium consumption by 10%,2.2727272727272725,24.050687127337433,GHCEA
Policy intervention to reduce sodium consumption by 10%,3.0303030303030303,32.464223298194355,GHCEA
Policy intervention to reduce sodium consumption by 10%,0.06666666666666667,0.5984693165546012,GHCEA
Policy intervention to reduce sodium consumption by 10%,6.666666666666667,69.22886559939181,GHCEA
Haemophilus influenzae type b (Hib) vaccine included in routine childhood immunization services,0.06666666666666667,1.381105092855387,GHCEA
Multidrug-resistant treatment as per WHO guidelines,1.7543859649122808,32.727662487253475,GHCEA
Policy intervention to reduce sodium consumption by 10%,8.333333333333334,83.25218564313852,GHCEA
Quadrivalent conjugate meningococcal vaccine,1.5151515151515151,9.810257551461728,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,58.8235294117647,68.16869646184179,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),1.4285714285714286,2.182440461024828,GHCEA
Policy intervention to reduce sodium consumption by 10%,1.5625,7.519066745969876,GHCEA
Cochlear implant,0.13513513513513514,3.9144851210244345,GHCEA
Policy intervention to reduce sodium consumption by 10%,0.08333333333333333,0.6351251867576841,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),4.761904761904763,1.677988999136341,GHCEA
Policy intervention to reduce sodium consumption by 10%,1.6666666666666667,14.797097572386546,GHCEA
Quadrivalent conjugate meningococcal vaccine,1.7241379310344827,10.969161602870669,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,25.0,10.247106824221422,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),4.0,8.862985179677965,GHCEA
Policy intervention to reduce sodium consumption by 10%,4.166666666666667,37.65170280017844,GHCEA
Antivenom therapy for snakebite,6.666666666666667,31.88862569638945,GHCEA
Policy intervention to reduce sodium consumption by 10%,2.2727272727272725,23.419407727402916,GHCEA
Policy intervention to reduce sodium consumption by 10%,0.15873015873015872,1.861190531513333,GHCEA
Antivenom therapy for snakebite,3.4482758620689653,26.78186821910268,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,71.42857142857143,73.37241374900529,GHCEA
Policy intervention to reduce sodium consumption by 10%,5.555555555555555,46.929652367711846,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),6.25,15.627298721897938,GHCEA
Policy intervention to reduce sodium consumption by 10%,0.9090909090909091,9.978444603001261,GHCEA
Policy intervention to reduce sodium consumption by 10%,0.8333333333333334,8.399475815055796,GHCEA
Policy intervention to reduce sodium consumption by 10%,1.0869565217391304,11.29993299309435,GHCEA
Policy intervention to reduce sodium consumption by 10%,0.6666666666666666,5.258217430195859,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),0.029411764705882353,47.2517730585198,GHCEA
Home HIV counseling and testing,0.7142857142857143,11.743455363073304,GHCEA
Lateral-flow immunochromatographic assay (TB-LAM Alere) for tuberculosis diagnosis,2.5,8.24102130741986,GHCEA
Benefit-based tailored treatment,0.0909090909090909,30.340234220706105,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),0.08333333333333333,92.85522845220751,GHCEA
Policy intervention to reduce sodium consumption by 10%,5.555555555555555,46.91586655830942,GHCEA
Xpert MTB/RIF automated DNA test to detect tuberculosis and rifampicin (RIF) resistance,1.0,8.041842544702765,GHCEA
Cochlear implant,0.07692307692307693,3.714209138088301,GHCEA
"Community health workers (CHW) visit patients twice yearly to increase hypertension adherence by monitoring blood pressure, teaching them about healthy lifestyle choices and encouraging follow-up visits",2.941176470588235,19.91408889498715,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,29.41176470588235,60.834089880504386,GHCEA
STI services in mobile clinic,9.09090909090909,117.43455363073302,GHCEA
Target-to-treat,0.058823529411764705,14.265004728277681,GHCEA
Quadrivalent conjugate meningococcal vaccine,1.3513513513513513,8.96245751615022,GHCEA
Pneumococcal conjugate vaccine - 1 dose,6.25,0.911696500387013,GHCEA
Policy intervention to reduce sodium consumption by 10%,2.631578947368421,27.362766059792513,GHCEA
Policy intervention to reduce sodium consumption by 10%,10.526315789473683,109.97864821498203,GHCEA
Policy intervention to reduce sodium consumption by 10%,0.14285714285714288,1.359550272127962,GHCEA
Policy intervention to reduce sodium consumption by 10%,0.12048192771084337,1.0829714157116805,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,71.42857142857143,184.8420423292249,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),2.7777777777777777,5.946053348391547,GHCEA
Haemophilus influenzae type b (Hib)-containing and pneumococcal conjugate vaccine - 2 doses each,4.545454545454545,81.48520047846783,GHCEA
Haemophilus influenzae type b (Hib) - 1 dose,4.545454545454545,0.9439183979775232,GHCEA
Policy intervention to reduce sodium consumption by 10%,5.0,39.612826265637416,GHCEA
Haemophilus influenzae type b (Hib)-containing and pneumococcal conjugate vaccine - 1 dose each,7.6923076923076925,1.2473523347219377,GHCEA
Quadrivalent conjugate meningococcal vaccine,1.5384615384615385,9.957044447493574,GHCEA
Pneumococcal conjugate vaccine - 2 dose,4.545454545454545,68.25256108452861,GHCEA
Haemophilus influenzae type b (Hib) - 2 doses,2.7027027027027026,9.667735649987707,GHCEA
Policy intervention to reduce sodium consumption by 10%,0.6666666666666666,6.069937934227113,GHCEA
Xpert MTB/RIF automated DNA test to detect tuberculosis and rifampicin (RIF) resistance,1.0,9.372710853157098,GHCEA
Xpert MTB/RIF automated DNA test to detect tuberculosis and rifampicin (RIF) resistance,1.1627906976744187,9.372710853157098,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),0.10526315789473685,10.82052797681551,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,250.0,1201.4732751399617,GHCEA
Policy intervention to reduce sodium consumption by 10%,1.7857142857142856,13.946122331278112,GHCEA
Policy intervention to reduce sodium consumption by 10%,1.7543859649122808,17.10077659569105,GHCEA
Policy intervention to reduce sodium consumption by 10%,1.2195121951219512,11.775491627058685,GHCEA
Policy intervention to reduce sodium consumption by 10%,11.11111111111111,102.11700315715916,GHCEA
Policy intervention to reduce sodium consumption by 10%,19.230769230769234,211.48171734348114,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),4.166666666666667,12.361531961129794,GHCEA
Tuberculosis diagnosis using LED fluorescence microscopy,32.25806451612903,150.6707480545254,GHCEA
"Intermittent preventive treatment in infants (IPTi) using sulfadoxine pyrimethamine (SP) against clinical malaria; at 2, 3, and 9 months.",333.3333333333333,2584.3202740743845,GHCEA
Tuberculosis diagnosis using Xpert for known HIV-positive cases,5.88235294117647,53.95641653303951,GHCEA
"Intermittent preventive treatment in infants (IPTi) using mefloquine (MQ) against clinical malaria; at 2, 3, and 9 months.",25.64102564102564,136.52846036741062,GHCEA
Malaria intermittent preventive treatment in infants (IPTi) using sulfadoxine-pyrimethamine (SP) through Expanded Programme on Immunization (EPI) in Ifakara,250.0,753.3537402726271,GHCEA
Tuberculosis diagnosis using Xpert for smear negative and known HIV-positive cases,4.545454545454545,31.193553308163466,GHCEA
Intermittent preventive treatment in pregnancy- with mefloquine in addition to cotrimoxazole prophylaxis,142.85714285714286,1457.2170888485123,GHCEA
Tuberculosis diagnosis using Xpert for smear negative and known HIV-positive cases with additional HIV testing,4.545454545454545,21.351737023769644,GHCEA
Urban Malaria Control Program,21.73913043478261,48.105720764396665,GHCEA
Policy intervention to reduce sodium consumption by 10%,6.666666666666667,58.77345732604582,GHCEA
Tuberculosis diagnosis using same-day LED fluorescence microscopy,24.390243902439025,190.1321344497582,GHCEA
Xpert MTB/RIF (mycobacterium tuberculosis/rifampicin) tuberculosis diagnostic test scale up,8.333333333333334,110.91041176235896,GHCEA
Tuberculosis diagnosis using Xpert for known HIV-positive cases with additional HIV testing,6.666666666666667,79.85549646889847,GHCEA
"Intermittent preventive treatment in infants (IPTi) using 3 days of chlorproguanil-dapsone (CD3) against clinical malaria; at 2, 3, and 9 months.",2.2222222222222223,4.59750804401435,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,111.1111111111111,400.4910917133206,GHCEA
Intermittent preventive treatment in pregnancy- with mefloquine,6.666666666666667,817.3541092005976,GHCEA
Quadrivalent conjugate meningococcal vaccine,1.492537313432836,10.277412672959905,GHCEA
Policy intervention to reduce sodium consumption by 10%,17.857142857142858,203.86902340796138,GHCEA
Maintenance drug treatment for major depression,0.8333333333333334,0.4436416470494359,GHCEA
HIV vaccine given to grade 1 students. Infected individuals given highly active antiretroviral treatment (HAART).,2.631578947368421,89.72527693134658,GHCEA
Continuation drug treatment,1.0,0.4436416470494359,GHCEA
Infected individuals given highly active antiretroviral treatment (HAART).,1.1494252873563218,20.47576832535858,GHCEA
Episodic drug treatment for major depression,0.7692307692307693,0.3194219858755939,GHCEA
"Scaling up of testing and treatment of HIV with universal antiretroviral treatment (ART), HIV testing services, conventional peer-educator outreach, mobile point-of-care night clinics",2.2222222222222223,48.99110212815857,GHCEA
HIV vaccine given to grade 1 students,9.09090909090909,173.5989053671706,GHCEA
Maintenance cognitive behavioral therapy:CBT is a nonpharmacological intervention that is effective in the treatment of depression alone or combined with drug therapy.,2.941176470588235,1.3309249411483077,GHCEA
Episodal cognitive behavioral therapy in the treatment of depression alone or combined with drug therapy.,1.3888888888888888,0.30713652488037874,GHCEA
Rotavirus vaccination,14.925373134328359,177.4566588197744,GHCEA
Policy intervention to reduce sodium consumption by 10%,1.2987012987012987,14.021051457123024,GHCEA
Quadrivalent conjugate meningococcal vaccine,1.4285714285714286,9.907629834850926,GHCEA
Policy intervention to reduce sodium consumption by 10%,6.666666666666667,53.9127035301772,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),5.555555555555555,17.13637263281083,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,50.0,26.26825541740081,GHCEA
Antivenom therapy for snakebite,8.333333333333334,19.600288760713383,GHCEA
Policy intervention to reduce sodium consumption by 10%,0.08333333333333333,0.7356068773716598,GHCEA
Cochlear implants,0.029411764705882353,0.16873850283972205,GHCEA
Policy intervention to reduce sodium consumption by 10%,0.9090909090909091,8.365160636577743,GHCEA
Policy intervention to reduce sodium consumption by 10%,9.09090909090909,90.84811884971384,GHCEA
Policy intervention to reduce sodium consumption by 10%,5.0,51.60290563418318,GHCEA
Policy intervention to reduce sodium consumption by 10%,4.761904761904763,49.62434530754317,GHCEA
An automated molecular assay for detection of tuberculosis and rifampin resistance from sputum samples,16.393442622950822,31.94219858755939,GHCEA
Smear-microscopy plus LF-LAM testing for rapid diagnosis of tuberculosis (LF-LAM is a low-cost urinary lateral flow assay for lipoarabinomannan (LAM)),28.57142857142857,52.88443474761488,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),4.761904761904763,14.519181176163357,GHCEA
Routine measles-containing vaccine followed by supplementary immunization,1000.0,5703.964033492748,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,125.0,420.29208667841294,GHCEA
Quadrivalent conjugate meningococcal vaccine,1.3333333333333333,8.70834203586679,GHCEA
Lateral-flow immunochromatographic assay (TB-LAM Alere) for tuberculosis diagnosis,10.309278350515465,42.02920866784129,GHCEA
Policy intervention to reduce sodium consumption by 10%,6.25,44.51998465122286,GHCEA
Xpert as replacement for smear-microscopy plus LF-LAM testing for rapid diagnosis of tuberculosis (Xpert is an automated molecular assay for detection of tuberculosis and rifampin resistance from sputum samples) (LF-LAM is a low-cost urinary lateral flow assay for lipoarabinomannan (LAM)),16.666666666666668,35.491331763954875,GHCEA
Typhoid vaccination-single dose,2.3255813953488373,9.242996023233317,GHCEA
Cochlear implants,0.12658227848101267,3.510131712918614,GHCEA
Xpert as replacement for smear-microscopy plus LF-LAM testing for rapid diagnosis of tuberculosis (Xpert is an automated molecular assay for detection of tuberculosis and rifampin resistance from sputum samples) (LF-LAM is a low-cost urinary lateral flow assay for lipoarabinomannan (LAM)),18.18181818181818,48.99110212815857,GHCEA
Second generation antipsychotic Olanzapine,0.15873015873015872,0.15417904867146479,GHCEA
Home based highly active anti-retroviral therapy (HAART) added to a package of home based care (HBAC) and cotrimoxazole prophylaxis,1.2987012987012987,47.67440054088763,GHCEA
Prenatal community distribution of misoprostol to pregnant mothers,14.705882352941176,23.349560371022942,GHCEA
Policy intervention to reduce sodium consumption by 10%,19.607843137254903,196.25337053059343,GHCEA
Policy intervention to reduce sodium consumption by 10%,0.7692307692307693,5.590399069537289,GHCEA
Policy intervention to reduce sodium consumption by 10%,2.0833333333333335,20.112201604054516,GHCEA
Policy intervention to reduce sodium consumption by 10%,2.941176470588235,30.24714839168913,GHCEA
New tuberculosis vaccine (40% efficacy),17.241379310344826,35.28588947412773,GHCEA
Policy intervention to reduce sodium consumption by 10%,2.7777777777777777,25.30516096869109,GHCEA
Rotavirus vaccination,7.6923076923076925,71.94188871071934,GHCEA
Policy intervention to reduce sodium consumption by 10%,37.03703703703704,421.62352940284296,GHCEA
Policy intervention to reduce sodium consumption by 10%,0.30303030303030304,2.340211248326607,GHCEA
Cochlear implants,0.004166666666666667,0.26949983621510737,GHCEA
Rotarix vaccine,0.625,0.8278145695364238,GHCEA
Policy intervention to reduce sodium consumption by 10%,5.555555555555555,55.772800997973505,GHCEA
Vitamin K prophylaxis,9.09090909090909,133.0924941148308,GHCEA
Condom promotion programme for female sex workers for HIV prevention,3.125,37.14209138088301,GHCEA
Brief smoking cessation advice + Nicotine replacement therapy (gum),200.0,0.28814135985025063,GHCEA
Brief smoking cessation advice + Varenicline,200.0,0.27638354088844524,GHCEA
Bupropion for smoking cessation,142.85714285714286,0.23311389674479935,GHCEA
Varenicline for smoking cessation,111.1111111111111,0.1498451858982558,GHCEA
Condom promotion programme for men who have sex with men for HIV prevention,9.09090909090909,29.68605816687675,GHCEA
Rotavirus vaccination,8.333333333333334,194.7695035826792,GHCEA
Brief smoking cessation advice + Bupropion,333.3333333333333,0.46111269470434496,GHCEA
Policy intervention to reduce sodium consumption by 10%,15.625,173.52346038439475,GHCEA
Nicotine replacement therapy (gum) for smoking cessation,76.92307692307693,0.11689990846115336,GHCEA
Needle and syringe programme for HIV prevention,0.625,4.392491554944909,GHCEA
"30% of people receiving ART for HIV 2015-2030 Viral Load scenario 7: Every 2 years, switching criteria of  confirmed VL >1000 copies/mL, with resistance test",0.18867924528301885,1.3713806709410694,GHCEA
"30% of people receiving ART for HIV 2015-2030 Viral Load scenario 3: Every year, switching criteria of confirmed VL >1000 copies/mL, with resistance test",0.17543859649122806,1.6650437128627704,GHCEA
"Needle and syringe program, methadone maintenance program, condom promotion for female sex workers and men who have sex with men, antiretroviral therapy program",3.8461538461538463,67.67414954991396,GHCEA
"30% of people receiving ART for HIV 2015-2030 Viral Load scenario 8: Every 2 years, switching criteria of  confirmed VL >400 copies/mL, with resistance test",0.18867924528301885,1.4993521680228776,GHCEA
Brief smoking cessation advice,10.526315789473683,5.038201669962049,GHCEA
"30% of people receiving ART for HIV 2015-2030 Viral Load scenario 5: Every 2 years, switching criteria of  confirmed VL >1000 copies/mL, no resistance test",0.19607843137254902,1.5670230861243812,GHCEA
3 doses of combined diphtheria-tetanus-pertussis-hepatitis B-Hib and 3 doses of Hep B vaccines,0.7692307692307693,3.320394863571662,GHCEA
Antiretroviral therapy programme (including prevention of mother-to-child transmission of HIV),5.88235294117647,106.47399529186463,GHCEA
Brief smoking cessation advice + Nicotine replacement therapy (patch),62.5,0.09898787245748025,GHCEA
"30% of people receiving ART for HIV 2015-2030 Viral Load scenario 4: Every year, switching criteria of  confirmed VL >400 copies/mL, with resistance test",0.16666666666666666,1.7195412676334727,GHCEA
Rotavirus vaccination,3.8461538461538463,29.576109803295726,GHCEA
Clozapine,0.9090909090909091,102.3788416267929,GHCEA
"30% of people receiving ART for HIV 2015-2030 Viral Load scenario 2: Every year, switching criteria of confirmed VL >400 copies/mL, no resistance test",0.2,1.6947261559613427,GHCEA
"30% of people receiving ART for HIV 2015-2030 Viral Load scenario 6: Every 2 years, switching criteria of  confirmed VL >400 copies/mL, no resistance test",0.2,1.608044632881564,GHCEA
Nicotine replacement therapy (patch) for smoking cessation,29.41176470588235,0.04890080064965828,GHCEA
Policy intervention to reduce sodium consumption by 10%,9.09090909090909,82.41871861791563,GHCEA
Rotavirus vaccination,29.41176470588235,362.97952940408396,GHCEA
Policy intervention to reduce sodium consumption by 10%,5.0,39.640355655943644,GHCEA
New tuberculosis vaccine (40% efficacy),28.57142857142857,98.12668526529671,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,333.3333333333333,1597.1099293779694,GHCEA
"Community-based therapeutic care, ready to use therapeutic food, a nutrient-dense food with a nutrient content/100 kcal that is similar to F100 milk",16.666666666666668,27.72760294058974,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),5.263157894736842,14.3367139082403,GHCEA
New tuberculosis vaccine (40% efficacy),250.0,1038.4329839908771,GHCEA
Dihydroartemisinin piperaquine for first line treatment of plasmodium falciparum malaria,142.85714285714286,29.358638407683255,GHCEA
New tuberculosis vaccine (40% efficacy),1000.0,7394.027450823932,GHCEA
Policy intervention to reduce sodium consumption by 10%,3.7037037037037037,33.9420650609506,GHCEA
Rotavirus vaccination,21.27659574468085,241.98635293605597,GHCEA
Rotavirus vaccination,23.25581395348837,275.36378092723606,GHCEA
Sickle cell disease screening using isoelectric focusing (IEF),1.1904761904761907,1.5047201143564812,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,111.1111111111111,110.91041176235896,GHCEA
Pneumococcal conjugate vaccination,7.142857142857142,62.38710661632693,GHCEA
Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,83.33333333333333,241.98635293605597,GHCEA
New tuberculosis vaccine (40% efficacy),200.0,726.6196221009868,GHCEA
